The FDA has cleared the initiation of a pivotal Phase 3 trial testing pridopidine in people with early, rapidly progressive ...
TOKYO, Oct 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin(R) for Injection 25 mg" (mecobalamin) has received the Good ...
In addition to ALS, pridopidine is in late-stage clinical development for HD, with Prilenia and Ferrer planning to initiate a confirmatory study in HD designed to confirm pridopidine's effects and ...
The Amyotrophic Lateral Sclerosis (ALS) treatment market is witnessing significant growth due to increasing awareness about this neurodegenerative disorder, affecting the central nervous system and ...
- AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS “Obtaining FDA Fast Track designation for AMX0114 ...
Spinal bulbar muscular atrophy (SBMA) causes a loss of motor neurons in the spinal cord and brainstem. It mainly affects facial and swallowing muscles and the muscles in the arms and legs. Previously, ...
The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback